期刊文献+

伽玛刀对垂体瘤肿瘤控制的效果分析 被引量:7

Control of Tumor with Gamma Knife in Patients with Pituitary Adenomas
原文传递
导出
摘要 目的评价伽玛刀治疗对垂体腺瘤肿瘤控制的疗效及相关并发症。方法回顾性分析2004年7月至2008年11月间,在四川大学华西医院接受伽玛刀治疗的191例垂体腺瘤患者的临床资料。伽玛刀治疗周边剂量11~33Gy,平均周边剂量26.3Gy,以45%~75%等剂量曲线覆盖病灶。术后定期复查鞍区MRI和血液激素水平,对复查结果进行对比分析。结果随访病例肿瘤控制有效率为95.2%,其中非功能性垂体腺瘤肿瘤控制有效率为100%,肿瘤体积明显缩小发生时间平均在伽玛刀治疗后11.4个月,功能性垂体腺瘤肿瘤控制有效率平均为93.8%,肿瘤体积明显缩小发生时间平均在伽玛刀治疗后18.6个月。伽玛刀治疗后新发垂体功能低下发生率为11.5%,伽玛刀治疗后无患者加重视力视野障碍。结论伽玛刀能有效地控制肿瘤生长,是安全有效的垂体腺瘤治疗手段。 Objective To evaluate the effectiveness and complications of gamma knife surgery for treating pituitary adenomas. Methods Retrospective analyses of 217 cases of pituitary adenomas (from July 2004 to November 2008) were performed in Sichuan university's West China Hospital. The patients were treated with an average dose of 26.3 Gy (range 11-33 Gy) and 45%-75% isodose line. Data from serial saddle area MRI and blood endocrine hormone tests were examined. Resnlts Of the 191 patients being followed up, 95.2% had their tumors effectively controlled. All non-functional pituitary adenoma were controlled, with the size of tumor shrinking significantly in an average of 11.4 months after gamma knife surgery. About functional pituitary adenoma were controlled, with the size of tumor shrinking significantly in an average of 18. 6 months. Pituitary hypofunction occurred in 11.5% of patients after the surgery. No patient experienced exacerbation of poor eyesight and visual field after gamma knife surgery. Conclusion Gamma knife can effectively control tumor growth and is a safe and effective treatment for pituitary adenoma.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2013年第3期458-461,共4页 Journal of Sichuan University(Medical Sciences)
关键词 垂体腺瘤 伽玛刀 磁共振 并发症 Pituitary adenomas Gamma knife MRI Complications
  • 相关文献

参考文献11

  • 1Hayashi M, Chernov M, Tamura N, et al. Gamma Knife robotic microradiosurgery of pituitary adenomas invading thecavernous sinus: treatment concept and results in 89 cases. J Neurooncol, 2010 ; 98(2) : 185-194.
  • 2Colin P, Jovenin N, Delemer B, et al. Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: prospective study of 110 patients. Int J Radiat Oncol Biol Phys,2005,62(2) :333-341.
  • 3Gopalan R, Schlesinger D, Vance ML, et al. Long-term outcomes after Gamma Knife radiosurgery for patients with a nonfunctioning pituitary adenoma. Neurosurgery,2011,69(2): 284-293.
  • 4Mackley HB, Reddy CA, Lee SY, et al. Intensity-modulated radiotherapy for pituitary adenomas: the preliminary report of the Cleveland Clinic experience. Int J Radiat Oncol Biol Phys, 2007,67(1) :232-239.
  • 5Laws ER, Sheehan JP, Sheehan JM, et al. Stereotactic radiosurgery for pituitary adenomas: a review of the literature. J Neurooncol, 2004 , 69 (1-3) : 257-272.
  • 6Wan H, Chihiro O, Yuan S. MASEP gamma knife radiosurgery for secretory pituitary adenomas: experience in 347 consecutive cases. J Exp Clin Cancer Res, 2009, 28: 36. PMCID: 2660297.
  • 7Swords FM, Monson JP, Besser GM, et al. Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy. Eur J Endocrinol, 2009 , 161 (6) : 819-828.
  • 8Kobayashi T. Long-term results of stereotactic gamma knife radiosurgery for pituitary adenomas. Specific strategies for different types of adenoma. Prog Neurol Surg, 2009 , 22 : 77-95.
  • 9Tinnel BA, Henderson MA, witt TC, et al. Endocrine response after gamma knife-based stereotactic radiosurgery for secretory pituitary adenoma. Stereotact Funct Neurosurg, 2008,86(5) :292-296.
  • 10Jagannathan J, Yen CP, Pouratian N, et al. Stereotactie radiosurgery for pituitary adenomas: a comprehensive review of indications, techniques and long-term results using the Gamma Knife. J Neurooncol,2009,92(3) :345-356.

同被引文献66

  • 1朱利峰,何占彪,王宏伟,张国荣,祁艺,徐雪衫.伽玛刀治疗功能性垂体腺瘤护理体会[J].内蒙古医科大学学报,2013,35(S2):493-495. 被引量:1
  • 2张宏伟,于春江,孙炜,杨军,闫长祥,寸恩浩.首选溴隐亭治疗侵袭性巨大泌乳素腺瘤的综合治疗[J].中华外科杂志,2006,44(22):1555-1557. 被引量:11
  • 3Colao A,Pivonello R,Di Somma C,et al.Medical therapy of pitu- itary adenomas:effects on tumor shrinkage[J]. Rev Endocr Metab Disord,2009,10(2) :111-123.
  • 4Colao A,Di Sarno A,Pivonello R,et al.I~mbardi G. Dopamine re- ceptor agonists for treating prolactinomas [J]. Expert Opin Investig Drugs, 2002,11 (6) : 787-800.
  • 5Cho KR,Jo KI,Shin HJ.Bromocriptine Therapy for the treatment of invasive prolactinoma:the single institute experience [J]. Brain Tumor Res Treat,2013,1 (2) :71-77.
  • 6Dos Santos Nunes V,E1 Dib R,Boguszewski CL,et al. Cabergo- line versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta- analysis[J].Pituitary, 2011,14 ( 3 ) : 259-265.
  • 7Di Sarno A,Landi ML,Cappabianca P,et al. Resistance to caber- goline as compared with bromocriptine in hyperprelactinemia: prevalence, clinical definition ,and therapeutic strategy[J]. J Clin Endocrinol bietab, 2001,86 ( 11 ) : 5256-5261.
  • 8Barlier A,Jaquet EQuinago2ide-a valuable treatment option for hy- perprolactinaemia[J].Eur J Endocrinol, 2006,154 (2) : 187-195.
  • 9Auriemma RS,Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas[J].Eur J Endocrinol, 2013,169 ( 3 ) : 359-366.
  • 10Dhawan V,Medcalf P,Stegie F,et al. Ray chaudhuri, retrospec- tive evaluation of cardio-pulmonary fibrotic side effects in symp- tom-atic patients from a group of 234 Parkinsen's disease pa- tients treated with cabergoline[J]. J Neural Transm,2005,112(5 ) : 661-668.

引证文献7

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部